of 43 /43
DVT Prophylaxis and DVT Prophylaxis and Pulmonary Embolism Pulmonary Embolism Karen Ruffin RN, MSN Ed. Karen Ruffin RN, MSN Ed.

DVT Prophylaxis and Pulmonary Embolism Karen Ruffin RN, MSN Ed

Embed Size (px)

Text of DVT Prophylaxis and Pulmonary Embolism Karen Ruffin RN, MSN Ed

  • Slide 1
  • DVT Prophylaxis and Pulmonary Embolism Karen Ruffin RN, MSN Ed.
  • Slide 2
  • Frequency in the US Up to 2 million people are affected annually by Venous Thromboembolism(VTE). Of those 2 million people it is estimated that 300,000 of them will develop and die from a Pulmonary Embolism (PE). The highest incidence of PE is with hospitalized patients. Autopsy shows that as many as 60% of patients dying in the hospital have had a PE, but the diagnosis is being missed 70% of the time. According to: Center for Disease Control (CDC), Department of Health and Human Services, Food and Drug Administration (FDA), The Surgeon General
  • Slide 3
  • Percentage if at risk for Development of a VTE All hospitalized patients, depending on acuity, have between a 10%-48% of developing a VTE All hospitalized patients, depending on acuity, have between a 10%-48% of developing a VTE Med-Surg patients placed on bed rest for a week (10%-13%). Med-Surg patients placed on bed rest for a week (10%-13%). Patients in the MICU (29%-33%). Patients in the MICU (29%-33%). Patients with Pulmonary Disease on bed rest for 3 or more days (20%-26%). Patients with Pulmonary Disease on bed rest for 3 or more days (20%-26%). Patients in the CCU with an MI (27%-33%). Patients in the CCU with an MI (27%-33%). Patients who are asymptomatic after a CABG (48%). Patients who are asymptomatic after a CABG (48%). Feied, C.F. & Handler, J.A., (2008)
  • Slide 4
  • Mortality and Morbidity Approximately 10% of the patients with an acute PE will die with in the first 60 minutes. Approximately 10% of the patients with an acute PE will die with in the first 60 minutes. 1/3 of those who live, the condition is diagnosed and treated. 1/3 of those who live, the condition is diagnosed and treated. 2/3 of the remaining patients go undiagnosed. 2/3 of the remaining patients go undiagnosed. Deaths that are a result of VTE/PE were shown to be the most common cause of preventable hospital deaths THAT IS HUGE! According to: Center for Disease Control (CDC), Department of Health and Human Services Food and Drug Administration (FDA), The Surgeon General
  • Slide 5
  • Mortality and Morbidity Race- Subtle population differences may exist, but the incidence is high in all racial groups. Race- Subtle population differences may exist, but the incidence is high in all racial groups. Sex- Women only when they are pregnant. Sex- Women only when they are pregnant. Age- Although the frequency for developing a PE increases with age, age alone is not an independent risk factor. It has more to do with co-morbidities. Age- Although the frequency for developing a PE increases with age, age alone is not an independent risk factor. It has more to do with co-morbidities.
  • Slide 6
  • Virchows Triad Vessel Damage Vessel Damage Vascular Constriction Vascular Constriction Blood Viscosity Blood Viscosity
  • Slide 7
  • Vessel Damage Endothelial cells allow blood to flow with ease through vessels. Factor VIII or Willibrands Factor Conditions/lifestyles that damage vessel walls: Past VTE- Pressure Ulcers Smoking- Cellulites High Cholesterol Varicose Veins
  • Slide 8
  • Vascular Constriction Trauma Surgery Insertion of central line Varicose Veins Restricted Mobility Sepsis Induction MI HF Stroke Any external force that cause damage to the vascular system can cause slow blood flow
  • Slide 9
  • Blood Viscosity Dehydrating Birth Control Pills High estrogen states Pregnancy Postpartum Cancer Sepsis Blood transfusions Obesity IBS Hematologic Disorders Elevated Blood Sugar Platelet Aggregation
  • Slide 10
  • Physiology of Clotting
  • Slide 11
  • Slide 12
  • What is the difference between a thrombus and an emboli? A thrombus is a clot that is stationary and a emboli is a thrombus that has broken off and is traveling. A thrombus is a clot that is stationary and a emboli is a thrombus that has broken off and is traveling.
  • Slide 13
  • Most Common Cause of a PE 90% are thrombi dislodged from deep veins in the calf. 90% are thrombi dislodged from deep veins in the calf. Some originate in the pelvis, particularly in pregnant women. Some originate in the pelvis, particularly in pregnant women. Fat embolus occur when long bones are broken (this is rare). Fat embolus occur when long bones are broken (this is rare).
  • Slide 14
  • What is a Pulmonary Embolism (PE)? Occlusion of a portion of the pulmonary vascular bed by an embolism. They can be a: Occlusion of a portion of the pulmonary vascular bed by an embolism. They can be a: Thrombus (Blood Clot) Tissue Fragment Lipids (Fat) Air Bubble
  • Slide 15
  • Pathophysiology Once the embolus is released into the blood stream they are distributed in: Once the embolus is released into the blood stream they are distributed in: 65% of the time both lungs 65% of the time both lungs 25% of the time right lung 25% of the time right lung 10% of the time left lung Lower lobes are 4 times more often upper lobes.
  • Slide 16
  • Pathophysiology Massive Occlusion- an embolus that occludes a major portion of the pulmonary circulation. Massive Occlusion- an embolus that occludes a major portion of the pulmonary circulation. Embolus with Infarction- An embolus that is large enough to cause an infarction (death) of a portion of lung tissue Embolus with Infarction- An embolus that is large enough to cause an infarction (death) of a portion of lung tissue Embolus without Infarction- Not sever enough to cause permanent lung injury. Embolus without Infarction- Not sever enough to cause permanent lung injury. Multiple Pulmonary Emboli- This can be chronic or recurrent. Multiple Pulmonary Emboli- This can be chronic or recurrent.
  • Slide 17
  • Risk Factors for DVT and PE Previous episode of thromboembolism Previous episode of thromboembolism Prolonged immobility Prolonged immobility Cancer Cancer Obesity Obesity Pregnancy Pregnancy Oral estrogen Oral estrogen Fever Fever Atrial fibrillation Atrial fibrillation CHF, Shock CHF, Shock Varicose veins Varicose veins Over 60 y/o Over 60 y/o Hematologic disorders Hematologic disorders Trauma Trauma Central Lines Central Lines Dehydration Dehydration Hypovolemia Hypovolemia Surgical Patients Surgical Patients
  • Slide 18
  • Prophylaxis Strategies The evidence based practice guidelines published by the ACCP in June 2008 incorporated data obtained from a comprehensive literature review of the most recent studies available. The recommendations are broken up in to different categories from general patient populations to specific groups and conditions. American College of Chest Physicians, (2008)
  • Slide 19
  • Understanding the Different Recommendation Categories Grade 1: Benefits outweigh risk Grade 2: Less certain about the magnitude of benefits versus risk Grade A: High quality evidence Grade B: Moderate quality evidence Grade C: Low quality evidence American College of Chest Physicians, (2008)
  • Slide 20
  • General Patient Population Every hospital should have a formal strategy for addressing VTE prophylaxis (Grade 1A) Mechanical methods of thromboprophylaxis should be used primarily in patients who have a high risk of bleeding (Grade 1A) It is recommended against the use of aspirin alone as thromboprophylaxis for VTE for any group of patients (Grade 1A) American College of Chest Physicians, (2008)
  • Slide 21
  • What about patients w/ a PICC line?????? We are a seeing and increased incidence of DVT in patients with PICC lines. We are a seeing and increased incidence of DVT in patients with PICC lines. How can we assess for it? How can we assess for it?
  • Slide 22
  • Clinical Manifestation of PE Massive Occlusion- Profound shock, hypotension, tachycardia, pulmonary hypertension, and chest pain. Massive Occlusion- Profound shock, hypotension, tachycardia, pulmonary hypertension, and chest pain. Embolus with Infarction- Pleural pain, pleural friction rub, pleural effusion, hemoptysis, fever, and leukocytosis. Embolus with Infarction- Pleural pain, pleural friction rub, pleural effusion, hemoptysis, fever, and leukocytosis. Recurrent PE- Occur in individuals who have had a history of previous emboli. Recurrent PE- Occur in individuals who have had a history of previous emboli.
  • Slide 23
  • Applying the Nursing Process Assessment Assessment Diagnosis Diagnosis Planning Planning Intervention Intervention Evaluation Evaluation
  • Slide 24
  • Assessment and Symptoms Homons sign Homons sign H&P H&P Cough Cough Sudden onset of SOB Sudden onset of SOB Agitation Agitation Lightheadness Lightheadness Fainting Fainting Dizziness Dizziness Sweating Sweating Anxiety Anxiety Rapid Breathing Rapid Breathing Tachycardia Tachycardia Air Hunger Air Hunger
  • Slide 25
  • What are your nursing diagnosis going to be??? Tell me your long and short term goals.
  • Slide 26
  • Diagnostics Arterial Blood Gases Arterial Blood Gases EKG EKG Echocardiogram Echocardiogram Chest x-ray Chest x-ray VQ scan VQ scan Spiral CT scan Spiral CT scan Pulmonary Angiogram Pulmonary Angiogram Pt, ptt, INR Pt, ptt, INR D-DImer D-DImer Split Fibrinogen Split Fibrinogen MRA MRA
  • Slide 27
  • WHAT ARE YOUR INTERVENTIONS FOR YOUR STATED GOALS? Remember to always have: AssessmentActionPsychosocialEducation For every goal!
  • Slide 28
  • Treatment Supportive Supportive Filters Filters Anticoagulants/Thrombolytics Anticoagulants/Thrombolytics Heparin Coumadin Streptokinase Retavase TPA
  • Slide 29
  • SO WHAT WILL WE EVALUATE AND WHY?
  • Slide 30
  • Cost of Prevention vs. Treatment???? V/Q scan- $1500 V/Q scan- $1500 ICU bed $9000 day ICU bed $9000 day Arterial Angiogram- $3200 Arterial Angiogram- $3200 Many other realted cost????? Many other realted cost????? Sequential stockings- $10 day Sequential stockings- $10 day Heparin subq- pennies a day Heparin subq- pennies a day Lovenox subq $15 a day Lovenox subq $15 a day
  • Slide 31
  • Prevention is KEY Intermittent Pneumatic Stockings Intermittent Pneumatic Stockings SCD Teds Early Ambulation Low Dose Anticoagulation Low Dose Anticoagulation Heprin Lovenox Arixtra
  • Slide 32
  • So, what does all of this mean to us?
  • Slide 33
  • Assessment and Documentation We must assess if a patient is at risk for the development of a VTE Document that assessment Communicate with the health care team that the patient is at risk for a VTE. Document that communication Education, Education, Education
  • Slide 34
  • Why are all those steps important???? The Joint Commission and the Centers for Medicare and Medicaid have implemented VTE quality measures for surgical patients which include the Surgical Care Improvement Project (SCIP 1 & SCIP 2). SCIP 1 evaluates if patients were identified as being at risk, was prophylaxis ordered appropriately. SCIP 2 examines if prophylaxis was actually received by patient. Surgical types include: ortho, gyn, urological, elective spine, intracraneal. Appropriate prophylaxis includes: LDUFH, Fundaparinux, LMWH, warfarin
  • Slide 35
  • Why are all those steps important???? The CMS has created guidelines on payment for service for healthcare providers that use evidence based practice to promote the best possible outcomes for its customers.
  • Slide 36
  • In 2005, section 5001(c) of the Deficit Reduction Act of 2005 (DRA) authorized the Secretary of the Department of Health and Human Services to select conditions that: (1) are high cost, high volume, or both; (2) are identified through ICD-9-CM coding as complicating conditions (CCs) or major complicating conditions (MCCs) that, when present as secondary diagnoses on claims, result in a higher-paying MS-DRG; and (3) are reasonably preventable through the application of evidence-based guidelines.
  • Slide 37
  • So what does that mean to the bedside nurse? We must encourage all healthcare members to follow best practices as outline by creditable bodies such as the ACCP. Our role in assisting with reimbursement for care provided is to appropriately assess our patients and determine who is at risk for VTE/PE. Next we must communicate this information with the physicians. Once orders are receive for thromboprophylaxis we should ensure that treatment is delivered as soon as possible or within 2 to 3 hours of receiving the orders.
  • Slide 38
  • The Power of Suggestion!! Dont ever underestimate it!!!!!!!
  • Slide 39
  • Case Studies 37y/o women presented to the ER 18 days s/p laparotomy for lyses of adhesions. 37y/o women presented to the ER 18 days s/p laparotomy for lyses of adhesions. Symptoms- CP, SOB, lightheadness, tachycardia. Symptoms- CP, SOB, lightheadness, tachycardia. She was seen by an NP and not by an MD. CBC, Cardiac Enzymes, and Chem 7 ordered and were normal. Pt was sent home and told to follow up with her primary in two days. She was seen by an NP and not by an MD. CBC, Cardiac Enzymes, and Chem 7 ordered and were normal. Pt was sent home and told to follow up with her primary in two days. Pt. suffered a nonfatal PE that night. She was awarded $1,000,000.00 Pt. suffered a nonfatal PE that night. She was awarded $1,000,000.00
  • Slide 40
  • Case Study Nurse was to D/C a pt. home. She noted a large reddened, raised, warm area on the pt. right ankle. The nurse documented it, but did not notify the physician. Nurse was to D/C a pt. home. She noted a large reddened, raised, warm area on the pt. right ankle. The nurse documented it, but did not notify the physician. The pt. suffered a fatal PE two days later. A claim was filed against the nurse and was settled for $4,000,000.00. The pt. suffered a fatal PE two days later. A claim was filed against the nurse and was settled for $4,000,000.00.
  • Slide 41
  • Case Study Pt. was admitted with a fractured right hip on Sat morning. Patient was started on Lovenox 30mg subq daily. That order was renew on Monday after the patient had an ORIF of the right hip. The order was missed for 2 days. The patient suffered a non-fatal PE was transferred to the ICU. The hospital stay was extended by 3 weeks. A claim was filed against several nurses and was settled for $1,500,000.00 and medical expenses. Pt. was admitted with a fractured right hip on Sat morning. Patient was started on Lovenox 30mg subq daily. That order was renew on Monday after the patient had an ORIF of the right hip. The order was missed for 2 days. The patient suffered a non-fatal PE was transferred to the ICU. The hospital stay was extended by 3 weeks. A claim was filed against several nurses and was settled for $1,500,000.00 and medical expenses.
  • Slide 42
  • -American College of Chest Physicians, (2008). Antithrombotic and Thrombolytic Therapy: American College Of Chest Physicians Evidence Based Clinical Practice Guidelines. 8th Edition. Volume 133/number 6 (Suppl) pages 67s-968s. -Center for Disease Control, (2008). Are you at risk for deep vein thrombosis? Retrieved from http://www.cdc.gov/Features/Thrombosis on December 12, 2008. -Center for Medicare and Medicaid Services, (2008). CMS improves patient safety for Medicare and Medicaid by addressing never events., CMS Manual System. -Feied, C.F. & Handler, J.A., (2008). Pulmonary Embolism. Retrieved from eMedicine.com on December 12, 2008. -Galson, S.K., (2008) The Surgeon General calls to action to prevent deep vein thrombosis. US Department of Health and Human Services Office of the Surgeon General. Retrieved from http://www.surgeongeneral.gov on December 12, 2008. -National Institute for Health, (2007). What is a Deep Vein Thrombosis? Retrieved from http://www.nhlbi.nih.gov/health/dci/Diseases/Dvt on December 12, 2008. -Sanofi-Aventis, (2008). The Coalition to Prevent Deep-Vein Thrombosis. Retrieve from, http://www.preventdvt.org on December 12, 2008. -Sumpio, B.E., Riley, J.T, Dardik, A. (2002). Cells in focus: endothelial cell. Department of Surgery, Yale University School of Medicine. Retrieve from http://www.ncbi.nlm.nih.gov on December 12, 2008.http://www.cdc.gov/Features/Thrombosishttp://www.surgeongeneral.govhttp://www.nhlbi.nih.gov/health/dci/Diseases/Dvt on December 12http://www.preventdvt.org http://www.ncbi.nlm.nih.gov
  • Slide 43
  • Now we will do an Evolve case study!